

Resource Summary Report

Generated by [RRID](#) on Jul 30, 2026

CD3

RRID:AB_2744387

Type: Antibody

Proper Citation

BD Biosciences Cat# 563546, RRID:AB_2744387

Antibody Information

URL: http://antibodyregistry.org/AB_2744387

Proper Citation: BD Biosciences Cat# 563546, RRID:AB_2744387

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: UCHT1

Antibody ID: AB_2744387

Vendor: BD Biosciences

Catalog Number: 563546

Alternative Catalog Numbers: 563548

Record Creation Time: 20250820T001522+0000

Record Last Update: 20250820T074732+0000

Ratings and Alerts

No rating or validation information has been found for CD3.

No alerts have been found for CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 45 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Jones RD, et al. (2026) Tunable differentiation of human CD4+ and CD8+ T cells from pluripotent stem cells. *Cell stem cell*, 33(1), 73.

Isshiki Y, et al. (2025) EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function. *Cancer cell*, 43(1), 49.

Rashleigh L, et al. (2025) Antibody-like recognition of a ?? T cell receptor toward a foreign antigen. *Structure (London, England : 1993)*.

Bi K, et al. (2025) Myeloid cells mediate interferon-driven resistance to immunotherapy in advanced renal cell carcinoma. *Immunity*, 58(11), 2814.

Tuomela K, et al. (2025) TYK2 inhibition enhances Treg differentiation and function while preventing Th1 and Th17 differentiation. *Cell reports. Medicine*, 6(9), 102303.

Agarwal R, et al. (2025) Chikungunya virus-specific CD4+ T cells are associated with chronic chikungunya viral arthritic disease in humans. *Cell reports. Medicine*, 6(5), 102134.

da Silva Antunes R, et al. (2025) Evolution of SARS-CoV-2 T cell responses as a function of multiple COVID-19 boosters. *Cell reports*, 44(7), 115907.

Wang L, et al. (2024) PD-L1-expressing tumor-associated macrophages are immunostimulatory and associate with good clinical outcome in human breast cancer. *Cell reports. Medicine*, 5(2), 101420.

Reilly NA, et al. (2024) Oleic acid triggers metabolic rewiring of T cells poisoning them for T helper 9 differentiation. *iScience*, 27(4), 109496.

Padoan B, et al. (2024) NKp44/HLA-DP-dependent regulation of CD8 effector T cells by NK cells. *Cell reports*, 43(4), 114089.

Radziszewska A, et al. (2024) Type I interferon and mitochondrial dysfunction are associated with dysregulated cytotoxic CD8+ T cell responses in juvenile systemic lupus erythematosus. *Clinical and experimental immunology*.

Mathews JA, et al. (2024) Single cell profiling of hematopoietic stem cell transplant recipients reveals TGF- β 1 and IL-2 confer immunoregulatory functions to NK cells. *iScience*, 27(12), 111416.

Tsao HW, et al. (2024) Targeting the aminopeptidase ERAP enhances antitumor immunity by disrupting the NKG2A-HLA-E inhibitory checkpoint. *Immunity*, 57(12), 2863.

Ryu H, et al. (2024) Merkel cell polyomavirus-specific and CD39+CLA+ CD8 T cells as blood-based predictive biomarkers for PD-1 blockade in Merkel cell carcinoma. *Cell reports. Medicine*, 5(2), 101390.

Reid KT, et al. (2024) Cell therapy with human IL-10-producing ILC2s limits xenogeneic graft-versus-host disease by inhibiting pathogenic T cell responses. *Cell reports*, 44(1), 115102.

Zhao Y, et al. (2024) Personalized drug screening using patient-derived organoid and its clinical relevance in gastric cancer. *Cell reports. Medicine*, 5(7), 101627.

Williams GP, et al. (2023) Unaltered T cell responses to common antigens in individuals with Parkinson's disease. *Journal of the neurological sciences*, 444, 120510.

Dubé M, et al. (2023) Spontaneous HIV expression during suppressive ART is associated with the magnitude and function of HIV-specific CD4+ and CD8+ T cells. *Cell host & microbe*, 31(9), 1507.

Nicolas A, et al. (2023) An extended SARS-CoV-2 mRNA vaccine prime-boost interval enhances B cell immunity with limited impact on T cells. *iScience*, 26(1), 105904.

Grünhagel B, et al. (2023) Reduction of IFN-I responses by plasmacytoid dendritic cells in a longitudinal trans men cohort. *iScience*, 26(11), 108209.